Biomedical Engineering Reference
In-Depth Information
initial estimates of the structural and functional requirements of the optimum
modulators. In this article studies expounded under benzopyrans and hERG K
+
modulators provide a glimpse of the role of QSAR and modeling approaches in lead
alteration and optimization. Advancements in retro-QSAR methodologies could
further help in translating the in silico results to wet laboratories.
Acknowledgements Authors thank Director, CDRI for extending the library facility and
Dr. Shreekant Deshpande, Faculty of Pharmacy, Hygia Institute of Pharmaceutical Education and
Research, Lucknow, for critical reading of the draft manuscript (CDRI communication No. 8062).
References
1. Hille B (1992) Ionic channels of excitable membranes, 2nd edn. Sinauer Associates,
Sunderland, MA
2. Camerino DC, Tricarico D, Desaphy JF (2007) Ion channel pharmacology. Neurotherapeutics
4:184-198
3. Verkman AS, Galietta LJ (2009) Chloride channels as drug targets. Nat Rev Drug Discov
8:153-171
4. Camerino DC, Desaphy JF, Tricarico D et al (2008) Therapeutic approaches to ion channel
diseases. Adv Genet 64:81-145
5. Doyle DA, Cabral JM, Pfuetzner RA et al (1998) The structure of the potassium channel:
molecular basis of K
+
conduction and selectivity. Science 280:69-77
6. Catterall WA (1993) Structure and modulation of Na
+
and Ca
2+
channels. Ann NY Acad Sci
707:1-19
7. Mackinnon R (1991) Determination of the subunit stoichiometry of a voltage-activated
potassium channel. Nature 350:232-235
8. Mackinnon R, Aldrich RW, Lee AW (1993) Functional stoichiometry of Shaker potassium
channel inactivation. Science 262:757-759
9. Rudy B (1988) Diversity and ubiquity of K channels. Neuroscience 25:729-749
10. Goldstein SAN, Wang KW, Ilan N et al (1998) Sequence and function of the two P domain
potassium channels: implications of an emerging superfamily. J Mol Med 76:13-20
11. Shieh C-C, Coghlan M, Sullivan JP et al (2000) Potassium channels: molecular defects,
diseases and therapeutic opportunities. Pharmacol Rev 52:557-593
12. Coghlan MJ, Carroll WA, Gopalakrishnan M (2001) Recent developments in the biology and
medicinal chemistry of potassium channel modulators: update from a decade of progress.
J Med Chem 44:1627-1653
13. Conti M (2004) Targeting K
+
channels for cancer therapy. J Exp Ther Oncol 4:161-166
14. Jahangir A, Terzic A (2005) K
ATP
channel therapeutics at the bedside. J Mol Cell Cardiol
39:99-112
15. Kaczorowski GJ, McManus OB, Priest BT et al (2008) Ion channels as drug targets: the next
GPCRs. J Gen Physiol 131:399-405
16. Sandhiya S, Dkhar SA (2009) Potassium channels in health, disease & development of
channel modulators. Indian J Med Res 129:223-232
17. Sanguinetti MC, Tristani-Firouzi M (2006) hERG potassium channels and cardiac arrhythmia.
Nature 440:463-469
18. Hansch C, Leo A (1979) Substituent constants for correlation analysis in. Wiley-Interscience,
New York
19. Stewart JJP (2004) Optimization of parameters for semiempirical methods IV: extension of
MNDO, AM1, and PM3 to more main group elements. J Mol Model 10:155-164
20. CS Chem3D Ultra
Cambridge Soft Corporation, Cambridge, USA
®
